nektar therapeutics’ president and ceo howard w robin to present at the jefferies  global nektar therapeutics president and ceo howard w robin to present at the jefferies  global healthcare conference in new york city news provided by nektar therapeutics jun    et share this article san francisco june   prnewswire  nektar therapeutics nasdaq nktr president and chief executive officer howard w robin is scheduled to present at the upcoming jefferies  global healthcare conference in new york city on wednesday june   at  am eastern time the presentation will be accessible via a webcast through a link posted on the investor relations events calendar section of the nektar website httpwwwnektarcom this webcast will be available for replay until july   about nektar nektar therapeutics has a robust rd pipeline and portfolio of approved partnered medicines in oncology pain immunology and other therapeutic areas in oncology nektar is developing nktr an immunostimulatory cdbiased agonist that is in phase  clinical development for patients with solid tumors onzeald™ etirinotecan pegol a longacting topoisomerase i inhibitor is being developed for patients with advanced breast cancer and brain metastases and is partnered with daiichi sankyo in europe in the area of pain nektar has an exclusive worldwide license agreement with astrazeneca for movantik™ naloxegol the first fdaapproved oncedaily oral peripherallyacting muopioid receptor antagonist pamora medication for the treatment of opioidinduced constipation oic in adult patients with chronic noncancer pain the product is also approved in the european union as moventig® naloxegol and is indicated for adult patients with oic who have had an inadequate response to laxatives nktr a wholly owned muopioid analgesic molecule for chronic pain conditions is in phase  development in hemophilia nektar has a collaboration agreement with baxalta for adynovate™ antihemophilic factor recombinant a longeracting pegylated factor viii therapeutic approved in the us and japan for patients over  with hemophilia a in antiinfectives the company has two collaborations with bayer healthcare cipro inhale in phase  for noncystic fibrosis bronchiectasis and amikacin inhale in phase  for patients with gramnegative pneumonia  nektars technology has enabled nine approved products in the us or europe through partnerships with leading biopharmaceutical companies including astrazenecas movantik™ baxaltas adynovate™ ucbs cimzia® for crohns disease and rheumatoid arthritis roches pegasys® for hepatitis c and amgens neulasta® for neutropenia nektar is headquartered in san francisco california with additional operations in huntsville alabama and hyderabad india further information about the company and its drug development programs and capabilities may be found online at httpwwwnektarcom movantik™ is a trademark and moventig® is a registered trademark of the astrazeneca group of companies adynovate™ is a trademark of baxalta inc onzeald™ is a trademark of nektar therapeutics contactinvestorsjennifer ruddock of nektar therapeutics   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesnektartherapeuticspresidentandceohowardwrobintopresentatthejefferiesglobalhealthcareconferenceinnewyorkcityhtml source nektar therapeutics related links httpwwwnektarcom jun    et preview preclinical data presented at asco  annual meeting demonstrate that singleagent nktr produces a large increase in tumorinfiltrating lymphocytes to provide durable antitumor activity jun    et preview nektar therapeutics announces executive management promotions my news release contains wide tables view fullscreen also from this source jul    et nektar announces topline data from human abuse potential study jul    et nektar presents new preclinical data for nktr a explore more news releases in similar topics health care  hospitals medical pharmaceuticals trade show news you just read nektar therapeutics president and ceo howard w robin to present at the jefferies  global healthcare conference in new york city news provided by nektar therapeutics jun    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search howard w robin president and chief executive officer nektar therapeutics timesjavascript is disabled market profiles login sign up login sign up   edit person howard w robin president and chief executive officer at nektar therapeutics location add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop howard w robin president and chief executive officer at nektar therapeutics location add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop howard robin joined nektar therapeutics in january  he has more than  years of successful biopharmaceutical experience managing clinical development and commercial operations most recently mr robin served as president and chief executive officer of sirna therapeutics a clinicalstage biotechnology company pioneering rnaibased therapies for serious diseases and conditions including agerelated macular degeneration amd hepatitis c asthma respiratory syncytial virus rsv and huntington’s disease during his tenure at sirna mr robin successfully relaunched the company and created significant shareholder value that led to its acquisition by merck for  billion  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags biopharmaceutical therapeutics topics of influence na na careers achievements investments related people edit view all howard w robincareer  jan nektar therapeutics president and chief executive officer berlex vice president of finance and business development and chief financial officer sirna therapeutics president and chief executive officer competencies edit view all howard w robineducation fairleigh dickinson university accounting and finance edit howard w robinachievements and recognitions add milestone no milestones has been recorded for howard w robin edit howard w robinlinks add link no links has been recorded for howard w robin howard w robininvestmentsacquisitions no investments has been recorded for howard w robin howard w robininvestments representing others no investment reps has been recorded for howard w robin howard w robinrelated people colleagues at nektar therapeutics stephen k doberstein senior vice president and chief scientific officer jan view all howard w robinrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies howard w robin  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in howard w robin dir president and chief executive officer at nektar therapeutics view full profile are you howard w robin claim your profile   sign up for equilar atlas and view howard w robins full profile with equilar atlas you can identify corporate executives in howard w robins network and community follow changes in howard w robins employment and moneyinmotion connect with howard w robin through your network of contacts howard w robins executive work history current dir president and chief executive officer nektar therapeutics past to view howard w robins complete executive work history sign up now age      howard w robins biography howard w robin age  has served as our president and chief executive officer since january  and has served as a member of our board of directors since february  mr robin served as chief executive officer president and a director of sirna therapeutics inc a biotechnology company from july  to november  and from january  to june  served as their chief operating officer president and as a director from  to  mr robin was corporate vice president and general manager at berlex laboratories inc a pharmaceutical products company that is a subsidiary of schering ag and from  to  he served as  read more howard w robin age  has served as our president and chief executive officer since january  and has served as a member of our board of directors since february  mr robin served as chief executive officer president and a director of sirna therapeutics inc a biotechnology company from july  to november  and from january  to june  served as their chief operating officer president and as a director from  to  mr robin was corporate vice president and general manager at berlex laboratories inc a pharmaceutical products company that is a subsidiary of schering ag and from  to  he served as vice president of finance and business development and chief financial officer from  to  mr robin was director of business planning and development at berlex he was a senior associate with arthur andersen  co prior to joining berlex he received his bs in accounting and finance from fairleigh dickinson university and serves as a member of its board of trustees source nektar therapeutics on    sign up for equilar atlas and view howard w robins full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like howard w robin more specifically youll be able to identify corporate executives in howard w robins network and community follow changes in howard w robins employment and moneyinmotion connect with howard w robin through your network of conections view full profile   search for over  executive profiles bio example howard w robin howard w robins connections  sign up now to view howard w robins  connections » gil m labrucherie senior vice president and chief financial officer nektar therapeutics michael a brown former chief executive officer and director symantec corporation maninder hora senior vice president pharmaceutical development and manufacturing operations nektar therapeutics dennis l winger board member accuray incorporated roy a whitfield board member nektar therapeutics bryan e roberts former executive vice president celldex therapeutics inc robert b chess chairman of the board nektar therapeutics irwin lerner former chairinterim presceo medarex john s patton former chief scientific officer nektar therapeutics john nicholson senior vice president and chief operating officer nektar therapeutics popular profiles sign up now to view more executive profiles » john j kita evp and cfo a o smith elon r musk ceo and chairman tesla thomas j lynch executive chairman te connectivity ltd jan koum board member facebook inc robert d perlmutter senior evp and coo the macerich company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   nektar therapeutics president and ceo howard w robin to present at the th annual jp morgan healthcare conference in san francisco ca data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in nektar therapeutics president and ceo howard w robin to present at the th annual jp morgan healthcare conference in san francisco ca january    san francisco jan   prnewswire  nektar therapeutics nasdaq nktr president and chief executive officer howard w robin is scheduled to present at the upcoming th annual jp morgan healthcare conference in san francisco on tuesday january   at  pm pacific time the presentation will be accessible via a webcast through a link posted on the investor relations events calendar section of the nektar website httpwwwnektarcom in addition the company will webcast the qa breakout session immediately following its presentation at  pm pacific time this webcast will be available for replay until february  about nektarnektar therapeutics has a robust rd pipeline and portfolio of approved partnered medicines in oncology pain immunology and other therapeutic areas in the area of oncology nektar is developing nktr an immunostimulatory cdbiased agonist that is in phase  clinical development for patients with solid tumors onzeald™ etirinotecan pegol a longacting topoisomerase i inhibitor is being developed for patients with advanced breast cancer and brain metastases and is partnered with daiichi sankyo in europe  in the area of pain nektar has an exclusive worldwide license agreement with astrazeneca for movantik™ naloxegol the first fdaapproved oncedaily oral peripherallyacting muopioid receptor antagonist pamora medication for the treatment of opioidinduced constipation oic in adult patients with chronic noncancer pain the product is also approved in the european union as moventig® naloxegol and is indicated for adult patients with oic who have had an inadequate response to laxatives the astrazeneca agreement also includes nktr an earlier stage development program that is a coformulation of movantik and an opioid nktr a wholly owned muopioid analgesic molecule for chronic pain conditions is in phase  development in hemophilia nektar has a collaboration agreement with baxalta for adynovate™ antihemophilic factor recombinant a longeracting pegylated factor viii therapeutic approved in the us and japan for patients over  with hemophilia a in antiinfectives the company has two collaborations with bayer healthcare cipro inhale in phase  for noncystic fibrosis bronchiectasis and amikacin inhale in phase  for patients with gramnegative pneumonianektars technology has enabled nine approved products in the us or europe through partnerships with leading biopharmaceutical companies including astrazenecas movantik™ baxaltas adynovate™ ucbs cimzia® for crohns disease and rheumatoid arthritis and amgens neulasta® for neutropenianektar is headquartered in san francisco california with additional operations in huntsville alabama and hyderabad india further information about the company and its drug development programs and capabilities may be found online at httpwwwnektarcommovantik™ is a trademark and moventig® is a registered trademark of the astrazeneca group of companies adynovate™ is a trademark of baxalta inc cimzia® is a registered trademark of ucb onzeald™ is a trademark of nektar therapeuticscontact jennifer ruddock of nektar therapeutics  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesnektartherapeuticspresidentandceohowardwrobintopresentatthethannualjpmorganhealthcareconferenceinsanfranciscocahtmlsource nektar therapeutics related stories nektar therapeutics president and ceo howard w robin to present at the th annual jp morgan healthcare conference in san francisco ca pr newswire   et shire announces fda approval of adynovate® antihemophilic factor recombinant pegylated for use in children and surgical settings pr newswire   et pipers  biopharma surprises for  sa breaking news   et analyst actions janney cuts price target on nektar therapeutics to  from  keeps rating at buy mt newswires   et chief executive officer robin howard w files to sell m of nktr on  mt newswires   et chief executive officer robin howard w exercises  sells m of nktr on  mt newswires   et biotech stocks on investors radar  vertex pharma nektar therapeutics cti biopharma and sage therapeutics pr newswire   et chief executive officer robin howard w files to sell m of nktr on  mt newswires   et chief executive officer robin howard w exercises  sells m of nktr on  mt newswires   et synopsys test solution deployed by leading automotive ic suppliers for higher quality reliability and functional safety pr newswire   et advertisement  no credit card required already a subscriber sign in nktr howard w robin insider trades for nektar therapeutics bulletin investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close nektar therapeutics nasdaq nktr go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus nektar therapeutics after hours  real time quotes jul    pm nktr quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual howard w robin mr howard w robin is president chief executive officer  director at nektar therapeutics he is on the board of directors at nektar therapeutics and fairleigh dickinson university mr robin was previously employed as president  chief executive officer by sirna therapeutics inc vice president  general manager by berlex laboratories inc a directorbusiness planning  development by berlex inc and a senior associate by arthur andersen llp he also served on the board at acologix inc the bay area bioscience association and biotechnology industry organization he received his undergraduate degree from fairleigh dickinson university transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr howard w robin president chief executive officer  director mr john nicholson chief operating officer  senior vice president mr gilbert m labrucherie chief financial officer  senior vice president dr ivan philip gergel chief medical officer  senior vpdrug development dr stephen k doberstein chief scientific officer  senior vice president dr mary tagliaferri vice presidentclinical development dr maninder hora senior vice presidentpharmaceutical development ms jillian b thomsen chief accounting officer  senior vpfinance ms jennifer ruddock senior vpinvestor relations  corporate affairs ms jodi a sievers directorinvestor relations  communications ms dorian hirth senior vphuman resources  facilities operations mr mark a wilson secretary vice president  general counsel dr carlo j di fonzo senior vpdrug development  regulatory affairs mr robert b chess chairman mr joseph j krivulka independent director mr r scott greer independent director mr dennis l winger independent director mr roy a whitfield independent director mr christopher a kuebler independent director mr lutz lingnau independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest psean spicer quits as white house press secretary over scaramucci hire pdo you tip your uber driver poil ends at a more than week low with opec output expected to rise psp  nasdaq poised for weekly gains even as stocks retreat record range peuro rallies to year high as hawkish view on ecb dominates pfed sets  goal for faster payment systems pwhite house briefs reporters after spicer quits as press secretary live blog phow realestate tv shows determine what buyers look for in a house pamazon paying publishers to post on new social network spark pwhat to do when like sean spicer you decide to quit your job pif you care about the planet don’t buy so much psan francisco seeks court order to force uber lyft to disclose records psept wti oil settles at bbl down  or  on nymex psept wti futures contract down  for the week pwhy one analyst calls this the ‘chart of the week month and potentially year’ pproofpoint started at buy with  stock price target at needham pi want to buy my brothers out of our home — but they want me to pay future sales fees pplanning for longevity the wisdom of the ages phollywood is using social causes to sell movie tickets pam i entitled to a spousal benefit loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  howard w robin  boulder co  intelius sign in we found howard w robin in boulder co howard w robin intelius found that howard w robin is a male between  and  years old from boulder co we have connected them to  addresses  phones and  relatives or associates also known as howard william robin get report now age howard w robin is in his s howard has lived in boulder co denville nj clifton nj howards relatives ginger monroy eric robin judith robin michael robin howard w robin zodiac signcapricorn gendermale professional status president at nektar therapeutics get report now want to know more about howard get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about howard or use our people search engine to find others get background check on howard w robin get a criminal check on howard w robin get a public record report on howard w robin get a people search report on howard w robin howard w robins contact information known cities lived in find out where howard w robin has lived as well as howard w robins phone numbers and email addresses howard w robin has lived in  states colorado address for howard w robin  m w boulder co has lived in boulder co denville nj get full address report phone numbers associated with howard w robin    san francisco ca    belvedere tiburon ca    boulder co get full phone report email addresses associated with howard w robin hncom hncom hncom get email report howard w robins education information known schools attended learn about howard w robins academic history find out which schools howard w robin attended the dates attended as well as the degrees howard w robin received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act howard w robin has attended  school fairleigh dickinson university howard w robin has a bs in accounting and finance howard w robins professional information information regarding howard w robins professional history find out previous places howard w robin has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act howard w robin has worked at  places company nektar therapeutics title president company nektar therapeutics title president and chief executive officer howard w robins experience title president company nektar therapeutics job details nektar therapeutics has a robust rd pipeline and portfolio of approved partnered medicines in oncology pain immunology and other therapeutic areas in the area of oncology nektar is developing nktr an immunostimulatory cdbiased agonist that is in phase  clinical development for patients with solid tumors onzeald etirinotecan pegol a longacting topoisomerase i inhibitor is being developed for patients with advanced breast cancer and brain metastases and is partnered with daiichi sankyo in europe in the area of pain nektar has an exclusive worldwide license agreement with astrazeneca for movantik naloxegol the first fdaapproved oncedaily oral peripherallyacting muopioid receptor antagonist pamora medication for the treatment of opioidinduced constipation oic in adult patients with chronic noncancer pain the product is also approved in the european union as moventig naloxegol and is indicated for adult patients with oic who have had an inadequate response to laxatives the astrazeneca agreement also includes nktr an earlier stage development program that is a coformulation of movantik and an opioid nktr a wholly owned muopioid analgesic molecule for chronic pain conditions is in phase  development in hemophilia nektar has a collaboration agreement with baxalta for adynovate antihemophilic factor recombinant a longeracting pegylated factor viii therapeutic approved in the us and japan for patients over  with hemophilia a in antiinfectives the company has two collaborations with bayer healthcare cipro inhale in phase  for noncystic fibrosis bronchiectasis and amikacin inhale in phase  for patients with gramnegative pneumonia nektars technology has enabled nine approved products in the us or europe through partnerships with leading biopharmaceutical companies including astrazenecas movantik baxaltas adynovate ucbs cimzia for crohns disease and rheumatoid arthritis and amgens neulasta for neutropenia nektar is headquartered in san francisco california with additional operations in huntsville alabama and hyderabad india title president and chief executive officer company nektar therapeutics job details company size  mil to less than  mil  employee range  to less than  nektar therapeutics has a robust rd pipeline and portfolio of approved partnered medicines in oncology pain immunology and other therapeutic areas in the area of oncology nektar is developing nktr an immunostimulatory cdbiased agonist that is in phase  clinical development for patients with solid tumors onzeald etirinotecan pegol a longacting topoisomerase i inhibitor is being developed for patients with advanced breast cancer and brain metastases and is partnered with daiichi sankyo in europe in the area of pain nektar has an exclusive worldwide license agreement with astrazeneca for movantik naloxegol the first fdaapproved oncedaily oral peripherallyacting muopioid receptor antagonist pamora medication for the treatment of opioidinduced constipation oic in adult patients with chronic noncancer pain the product is also approved in the european union as moventig naloxegol and is indicated for adult patients with oic who have had an inadequate response to laxatives the astrazeneca agreement also includes nktr an earlier stage development program that is a coformulation of movantik and an opioid nktr a wholly owned muopioid analgesic molecule for chronic pain conditions is in phase  development in hemophilia nektar has a collaboration agreement with baxalta for adynovate antihemophilic factor recombinant a longeracting pegylated factor viii therapeutic approved in the us and japan for patients over  with hemophilia a in antiinfectives the company has two collaborations with bayer healthcare cipro inhale in phase  for noncystic fibrosis bronchiectasis and amikacin inhale in phase  for patients with gramnegative pneumonia nektars technology has enabled nine approved products in the us or europe through partnerships with leading biopharmaceutical companies including astrazenecas movantik baxaltas adynovate ucbs cimzia for crohns disease and rheumatoid arthritis and amgens neulasta for neutropenia nektar is headquartered in san francisco california with additional operations in huntsville alabama and hyderabad india additional professional information on howard w robin see howard w robins linkedin profile howard w robins social network and potential email matches find out potential social network profiles and potential email usernamed for howard w robin howard w robins known social networks and potential email matches find all of howard w robins social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches howard robin username matches howardrobin robinhoward howardrobin robinhoward howardrobin robinhoward howardrobin robinhoward hrobin popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches h robin intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here unavailable  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries this feature is temporarily unavailable copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top sbgi log in for events holx caty gmed aehr pbf log in for events ryi tier etm sons find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  nktr stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsnktr nektar therapeutics    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all ema panel recommends against nektar daiichi sankyos breast cancer drug reuters –  am et  european regulators on friday recommended against granting approval to a breast cancer drug being developed by nektar therapeutics nktr and daiichi sankyos german unit the european medicines agency said its committee of experts refused authorisation to market the investigational drug onzeald as a firstline treatment for adults with advanced breast cancer who have already received other treatment briefeu medicines agency recommends approval of novartis leukaemia drug reuters –  am et  eu medicines agency  eu medicines agency recommendations for july   eu medicines agency recommends approval of pfizer inc and merck kgaa avelumab drug for cell carcinoma‍​  eu medicines agency recommends approval of sanofi and regeneron dupixent drug for severe eczema nektar announces topline data from human abuse potential study for nktr a firstinclass investigational opioid to treat chronic pain pr newswire –  am et  san francisco july    nektar therapeutics  announced positive topline results from an oral human abuse potential study of nktr a firstinclass opioid analgesic nektar presents new preclinical data for nktr a firstinclass regulatory t cell stimulator at th world congress of inflammation in london pr newswire –  am et  san francisco july    nektar therapeutics nktr today announced positive preclinical results for nktr a firstinclass resolution therapeutic for autoimmune disease daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics pr newswire –  am et  new york july   if you want a stock review on juno lxrx nk or nktr then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister juno therapeutics  on thursday shares in seattle washington headquartered juno therapeutics inc juno recorded a trading volume of  million shares nektar to webcast presentation at jefferies  global healthcare conference in new york city pr newswire –  pm et  san francisco june    nektar therapeutics nktr announced today that its corporate presentation will be webcast at the upcoming jefferies  global healthcare conference in new york city on wednesday june   at  am eastern time briefnektar presents findings from two phase  clinical studies of nktr reuters –  am et  nektar therapeutics nktr  presented new findings from two phase  clinical studies of nktr nektars lead immunooncology candidate  nektar therapeutics nktr  nktr monotherapy demonstrated a favorable safety profile with no immunerelated adverse events  data from blood and tumor samples show that nktr increases immune cells in blood and tumor microenvironment nektar presents new clinical data from two studies of nktr a cdbiased agonist at  american society of clinical oncology asco annual meeting pr newswire –  am et  chicago and san francisco june   nektar therapeutics nktr today announced that it presented new findings from two phase  clinical studies of nktr nektars lead immunooncology candidate a cdbiased agonist at the  american society of clinical oncology annual meeting biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics pr newswire –  am et  new york may   the biotech space consists of companies engaged in the research and development of new drugs medical devices and procedures httpstockcallerscomregistration juno therapeutics juno   shares in seattle washington headquartered juno therapeutics inc juno rose  ending wednesdays trading session at  the stock recorded a trading volume of  shares new research collaboration between nektar and takeda to explore combination cancer therapy approaches with nktr a cdbiased agonist and five takeda cancer therapy compounds pr newswire –  am et  san francisco may    nektar therapeutics announced today that takeda pharmaceutical company limited tkphf and nektar have entered into a research collaboration to explore the combination of nektars lead immunooncology candidate the cdbiased agonist nktr with five oncology compounds from takedas cancer portfolio nektar therapeutics announces data presentations at asco  pr newswire –  am et  san francisco may    nektar therapeutics nktr today announced its presence at the upcoming  american society of clinical oncology annual meeting where it will share updated data from clinical studies of nktr nektar to webcast presentation at ubs global healthcare conference  in new york pr newswire –  pm et  san francisco may    nektar therapeutics nktr announced today that its corporate presentation will be webcast at the upcoming ubs global healthcare conference on monday may   at  pm eastern time briefnektar therapeutics reports q revenue  million reuters –  pm et  nektar therapeutics nktr  nektar therapeutics nktr reports financial results for the first quarter of   q loss per share   q revenue  million versus ibes view  million  q earnings per share view   thomson reuters ibes source text for eikon further company coverage nektar therapeutics reports financial results for the first quarter of  pr newswire –  pm et  san francisco may    nektar therapeutics  today reported its financial results for the first quarter ended march   cash and investments in marketable securities at march   were  million as compared to  million at december   nektar appoints brian l kotzin md as head of clinical development for nektars immunology program pr newswire –  am et  san francisco may    nektar therapeutics  today announced the appointment of brian kotzin md as head of clinical development for nektars immunology program in this newlycreated role dr kotzin will lead clinical development for nktr a firstinclass regulatory t cell stimulator being developed for the treatment of immune and inflammatory disorders nektar to announce financial results for the first quarter of  on tuesday may   after close of usbased financial markets pr newswire –  am et  san francisco may    nektar therapeutics  will announce its financial results for the first quarter ended march   on tuesday may   after the close of usbased financial markets page page  todays and upcoming events aug  nktr to announce q earnings after market unconfirmed past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe insider trading  robin howard w  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  robin howard w select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view sale  pm nektar therapeutics nktr robin howard wpresident  ceodirector    indirectdirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view disposition  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view disposition  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view option award  pm na nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm nana nektar therapeutics nktr robin howard wpresident  ceodirector   direct view exercise  pm  nektar therapeutics nktr robin howard wpresident  ceodirector   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement